Ganglioside composition of human neuroblastomas correlation with prognosis A pediatric oncology group study
β Scribed by Cara-Lynne Schengrund; Mary Ann Repman; Stephen J. Shochat
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 590 KB
- Volume
- 56
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
The ganglioside composition of neuroblastoma samples from 53 patients was determined. Tumor sites included the adrenal5 (15), and the thoracic (to), abdominal (15), and pelvic (3) areas. Age of the patients at the time of surgery ranged from 1 day to over 10 years and the Stage of the tumors from A to D. Differences in ganglioside patterns were observed, with neuroblastomas from patients who were either disease positive or dead of disease tending to have more monosialogangliosides and fewer gangliotetraose gangliosides of the B series (Gal-GalNAc-Gal-Clc-Cer, G I b , and Gal-GalNAc-Gal-Glc-Cer, GDIb) NeuNAc NeuNAc-NeuNAc NeuNAc-NeuNAc than tumors from patients who were disease-free. More specifically, six of the seven patients lacking G l b died of disease, suggesting that the absence of
π SIMILAR VOLUMES
Histologic grading (HG) of neuroblastomas (NB) of prognostic significance is based on the presence or absence of calcification and low mitotic rate ( ~1 0 1 1 0 high power fields). Mitosis Karyorrhexis Index (MKI) is the main feature used for prognostic categorization in Shimada classification and c
From October 87 to April 92,172 children were admitted in the N-1-87 protocol of the Spanish Society of Pediatric Oncology for the diagnosis and treatment of neuroblastoma. Forty-eight were considered Evans stage Ill, 33 of them being older than 1 year. All children were treated with induction chemo
Background. The objectives of this study were to compare vincristine/actinomycin D/cyclophosphamide/adriamycin (VACA) with VACA plus imidazole carboxamide (DTIC) (VACAD) therapy in regards to complete/partial response and event free survival rates in children and adolescents with metastatic non-rhab
## Abstract To determine the maximum tolerated dose of 5βfluorouracil administered as a 120βhour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l